Navigation Links
Shire Presents Data at ACMG for Fabry and Gaucher Patients Who Switched to Replagal® (agalsidase alfa) and VPRIV® (velaglucerase alfa for injection)
Date:3/21/2011

CAMBRIDGE, Mass., March 21, 2011 /PRNewswire/ -- Shire plc (LSE: SHP, Nasdaq: SHPGY), the global specialty biopharmaceutical company, presented new data for Replagal® (agalsidase alfa) in patients with Fabry disease, and VPRIV® (velaglucerase alfa for injection) in patients with type 1 Gaucher disease, at the 2011 American College of Medical Genetics' (ACMG) Annual Clinical Genetics Meeting, held in Vancouver, BC, from March 16-20, 2011.  

Data from clinical programs evaluating the safety of switching from Fabrazyme® (agalsidase beta) to Replagal and long-term safety and efficacy of switching from Cerezyme® (imiglucerase) to VPRIV were presented.

Preliminary data from Shire's Replagal study 059, an ongoing, multicenter, open-label clinical study, was presented for the first time.  This data, following 3 months of treatment, suggests that switching from Fabrazyme to Replagal 0.2 mg/kg every other week is generally well tolerated. This ongoing study includes 70 Fabry patients in the US under Shire's treatment protocol who were switched to Replagal during the continuing Fabrazyme supply shortage. The safety events observed in this study were similar to those seen historically in patients treated with Replagal.

Data from the 52 patients in Shire's VPRIV study 044, the extension study for studies 034 and 039, were presented. Data from study 058, Shire's treatment protocol in the US, in 205 type 1 Gaucher patients who switched from Cerezyme were also presented. Taken together, these studies include data from ongoing treatment in more than 250 patients, representing the largest and most comprehensive set of studies to date for Gaucher disease. This collection of long-term data (up to 2 years) adds to the growing body of clinical evidence which supports the use of VPRIV in patients who have previously been treated with imiglucerase.

<
'/>"/>
SOURCE Shire plc
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. Shire Reports Positive Signal Finding Study of Investigative Use of Vyvanse(R) (lisdexamfetamine dimesylate) Capsules as Adjunctive Treatment in Major Depressive Disorder
2. Shire plc: Continued Excellent Performance in Q3, Full Year Earnings Expectations Increased, New Value in Pipeline Emerging
3. Shire Announces Results of the Tender Offer for Movetis NV and Commencement of Squeeze-Out Tender Period
4. Reportlinker Adds Shire plc: PharmaVitae Profile
5. Shire Announces European Approval of VPRIV(R) (velaglucerase alfa) for the Treatment of Type 1 Gaucher Disease
6. Shire plc - Statement re ProAmatine
7. Shire Proposes to Expand Specialist Gastrointestinal Portfolio
8. Lialda(R) - Shire Files Suit Against Cadila Healthcare Limited, Doing Business as Zydus Cadila and Zydus Pharmaceuticals (USA), Inc.
9. Shire Receives CHMP Positive Opinion for VPRIV(TM) (velaglucerase alfa) for the Treatment of Type 1 Gaucher Disease in the European Union
10. Shire plc Appoints Two New Board Directors
11. INTUNIV(TM) - Shire Files Suit Against Anchen Pharmaceuticals, Inc. and Anchen, Inc.
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/19/2014)... Aug. 19, 2014 CSSi, the leader in ... announced the formation of the company,s Medical and Clinical ... addition of Dr. William E. Gannon, Jr. ... The MCAB, with Dr. Gannon,s ... therapeutic areas and set strategic goals for the advancement ...
(Date:8/19/2014)... Scottsdale, AZ (PRWEB) August 19, 2014 ... the launch of its online sales skills training ... their sales skills. , MedTech clinical staff spend the ... at a hospital, standalone medical center, or physician practice ... administrative staff. But why stop there? Sales Horizons believes ...
(Date:8/18/2014)... FREDERICK, Md. , Aug. 18, 2014 ... the maker of advanced consumer medical devices ... Kotak was interviewed by CEOLIVE.TV as ... The entire interview is available at ... interview Dr. Kotak explains to investors the ...
(Date:8/18/2014)... According to a new ... Science Reagents Market(Products- PCR Reagent Kits, Cell and ... Reagents and Others; End Users- Commercial and Contract ... Forensic Laboratories)- Global Industry Analysis, Size, Share, Growth, ... life science reagents market was valued at USD ...
Breaking Biology Technology:CSSi Appoints Dr. William E. Gannon, Jr. to Newly Formed Medical and Clinical Advisory Board 2CSSi Appoints Dr. William E. Gannon, Jr. to Newly Formed Medical and Clinical Advisory Board 3Sales Horizons Launches a New Online Sales Training Course for MedTech Clinical Staff to Develop Their Sales Skills 2Sales Horizons Launches a New Online Sales Training Course for MedTech Clinical Staff to Develop Their Sales Skills 3BioElectronics EVP Dr. Deepak Kotak Interviewed on CEO Live 2BioElectronics EVP Dr. Deepak Kotak Interviewed on CEO Live 3Global Life Science Reagents Market Expected to Reach USD 25.7 Billion in 2019: Transparency Market Research 2Global Life Science Reagents Market Expected to Reach USD 25.7 Billion in 2019: Transparency Market Research 3Global Life Science Reagents Market Expected to Reach USD 25.7 Billion in 2019: Transparency Market Research 4Global Life Science Reagents Market Expected to Reach USD 25.7 Billion in 2019: Transparency Market Research 5
... and their Owners, ROCKVILLE, Md., June 23 ... a retriever retrieve? Why do Yorkshire terriers live,longer than ... be related,to a Great Dane?, (Photo: http://www.newscom.com/cgi-bin/prnh/20080623/AQM507 ... length and behavior more than any,other animal, and until ...
... NEW YORK, June 23 Medicsight PLC, a,subsidiary of ... an industry,leader in the development of Computer-Aided Detection (CAD) ... and Lucan Toh,(Director of Business Development) will be presenting ... 24th June., The conference will be held from ...
... Event June 27-28, 2008, NOVATO, Calif., June ... (OTC Bulletin Board:,RPTP), today announced that Ted Daley, ... Cystinosis Foundation Ireland,s 5th,International Cystinosis Conference to be ... City, Charlemont Place, Dublin 2, in Dublin, Ireland., ...
Cached Biology Technology:DNA Study Unlocks Mystery to Diverse Traits in Dogs 2DNA Study Unlocks Mystery to Diverse Traits in Dogs 3Medicsight to Present at Piper Jaffray Annual Europe Conference 2Raptor Pharmaceuticals Corp. Announces Presentation at 5th International Cystinosis Conference 2008 2Raptor Pharmaceuticals Corp. Announces Presentation at 5th International Cystinosis Conference 2008 3Raptor Pharmaceuticals Corp. Announces Presentation at 5th International Cystinosis Conference 2008 4Raptor Pharmaceuticals Corp. Announces Presentation at 5th International Cystinosis Conference 2008 5
(Date:8/20/2014)... few years, Virginia Tech,s Wu Feng has built upon ... the "Computing in the Cloud" program, and synergistically complemented ... award from the Air Force on "big computing" for ... the National Institutes of Health on "big data" for ... "parallel computing" aspects from each grant, he was able ...
(Date:8/20/2014)... new gene therapy developed by researchers at the University ... protect mice from a life-threatening heart condition caused by ... avenue," said Yi Lai, Ph.D., the leading author of ... School of Medicine,s Department of Molecular Microbiology and Immunology. ... this could lead to a treatment for people with ...
(Date:8/20/2014)... (PS1) absorbs light and its energy is finally ... biomass. Photovoltaic devices, mostly build from silicon based ... One approach for the development of cheaper and ... the isolated membrane protein complexes of photosynthesis. Prof. ... PS1 from thermophilic cyanobacteria that live in a ...
Breaking Biology News(10 mins):The internet was delivered to the masses; parallel computing is not far behind 2The internet was delivered to the masses; parallel computing is not far behind 3The internet was delivered to the masses; parallel computing is not far behind 4Gene therapy protects mice from lethal heart condition, MU researchers find 2A semi-artificial leaf faster than 'natural' photosynthesis 2
... John Bell said QUT had worked with a Canberra-based company ... both windows and energy generators in houses or commercial buildings. ... significant difference to home and building owners energy costs and ... on onsold. Professor Bell said the glass was one ...
... dramatically reduce damage caused by strokes the UK National ... (10 April). Speaking at the conference in Edinburgh, ... explain how combining scaffold microparticles with neural stem cells ... temporary loss of blood supply to the brain which ...
... 9, 2008) A study published in the April ... suggests an association between high egg consumption and all-cause mortality, ... an explanation. The researchers, Djouss and Gaziano, analyzed data from ... a 20 year period. The fact is, healthy adults ...
Cached Biology News:Scientists ask whether microscaffolding can help stem cells rebuild brain after stroke damage 2Statement by the American Egg Board and Egg Nutrition Center on AJCN study on egg consumption 2
The iEMS Incubator/Shaker is a high performance microplate incubator and orbital shaker. Its superior temperature control and efficient orbital shaking reduce incubation times. -...
... Source: Pseudomonas atlantica Description: Beta-Agarase is ... fragments from low-melting-temperature agarose. Beta-Agarase digests ... Tested User Friendly Properties: Heat Inactivation: ... Da Optimum pH: 6.5 Purity: Tested ...
... modified nucleotide structure called a ?cap? ... most naturally-occurring eukaryotic mRNAs and many ... for a portion of the GTP ... reaction results in the synthesis of ...
...
Biology Products: